ONCO — Onconetix Inc
NASDAQ · Healthcare · Biotechnology
$0.63
-$0.02 (-3.05%)
Onconetix Inc (ONCO) is a biotechnology company listed on NASDAQ. It is led by David Allan White C.A., C.P.A., ICD.D, based in 201 East Fifth Street, Cincinnati, OH, United States, 45202, with about 2 employees. Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.
Latest reported ONCO revenue for 2025-09-30 was $303.7K. Net income was -$8.8M. Revenue was up 185.1% from 2025-06-30 to 2025-09-30. ONCO currently screens at market cap $3.7M and trailing P/E 0.0.
Use this ONCO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ONCO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ONCO SEC filings page. Lician reads the product cache first so this HTML stays unique to Onconetix Inc even when a live quote feed is slow.
About Onconetix Inc
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.
ONCO Key Statistics
Market Cap
$3.66M
Volume
55,110
Previous Close
$0.66
Day Range
$0.64 – $0.66
P/E Ratio
0.00
P/B Ratio
0.34
EPS
-$21.45
Revenue
$2.52M
Net Income
-$58.69M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+4217.3%
Profit Margin
-2325.2%
Employees
2
ONCO Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $2.52M | $58.47K | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$58.69M | -$37.41M | -$13.42M | -$3.42M |
| EPS (Diluted) | -$21.45 | -$87.45 | -$1.10 | -$1.26 |
Total Assets
$28.18M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$600.00K
Operating Cash Flow
-$10.50M
Free Cash Flow
$0.00
Onconetix Inc Company Information
- Chief Executive Officer
- David Allan White C.A., C.P.A., ICD.D
- Headquarters
- 201 East Fifth Street, Cincinnati, OH, United States, 45202
- Website
- www.onconetix.com
- Phone
- 513 620 4101
- IPO / Founded
- 2022-02-18
- Sector
- Healthcare
- Industry
- Biotechnology